Thrombophilia and anticoagulation in pregnancy: indications, risks and management

References

• Royal College of Obstetricians and Gynaecologist, Thromboprophylaxis During Pregnancy, Labour and After Vaginal Delivery. Guideline No. 37. London, RCOG Press. 2004
   Google Scholar
• Bates S M, Greer I A, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 844S–886S
   PubMed Web of Science ®Google Scholar
• Martinelli I, Legnani C, Bucciarelli P, Grandone E, De S V, Mannucci P M. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800–803
   PubMed Web of Science ®Google Scholar
• Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901–908
   PubMed Web of Science ®Google Scholar
• Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101: 6–14
   PubMed Web of Science ®Google Scholar
• Greer I A. Anticoagulants in pregnancy. J Thromb Thrombolysis 2006; 21: 57–65
   PubMed Web of Science ®Google Scholar
• Gerhardt A, Scharf R E, Zotz R B. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77–85
   PubMed Web of Science ®Google Scholar
• Franchini M. Haemostasis and pregnancy. Thromb Haemost 2006; 95: 401–413
   PubMed Web of Science ®Google Scholar
• Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114: 409–414
   PubMed Web of Science ®Google Scholar
• Lockwood C J. Pregnancy-associated changes in the hemostatic system. Clin Obstet Gynecol 2006; 49: 836–843
   PubMed Web of Science ®Google Scholar
• Robertson L, Greer I. Thromboembolism in pregnancy. Curr Opin Obstet Gynecol 2005; 17: 113–116
   PubMed Web of Science ®Google Scholar
• Zotz R B, Gerhardt A, Scharf R E. Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy. Semin Thromb Hemost 2003; 29: 143–154
   PubMed Web of Science ®Google Scholar
• Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe G D, Walker I D, Greaves M, Brenkel I, Regan L, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171–196
   PubMed Web of Science ®Google Scholar
• Van Cott E M, Laposata M, Prins M H. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 126: 1281–1295
   PubMed Web of Science ®Google Scholar
• Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222–1231
   PubMed Web of Science ®Google Scholar
• Haemostasis and thrombosis task force, British committee for standards in haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512–528
   PubMed Web of Science ®Google Scholar
• Lane D A, Grant P J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517–1532
   PubMed Web of Science ®Google Scholar
• DeMoerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106–113
   PubMed Web of Science ®Google Scholar
• Ohira T, Cushman M, Tsai M Y, Zhang Y, Heckbert S R, Zakai N A, Rosamond W D, Folsom A R. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007; 5: 1455–1461
   PubMed Web of Science ®Google Scholar
• Kyrle P A, Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163–1174
   PubMed Web of Science ®Google Scholar
• Greer I A. The challenge of thrombophilia in maternal–fetal medicine. N Engl J Med 2000; 342: 424–425
   PubMed Web of Science ®Google Scholar
• Ye Z, Liu E H, Higgins J P, Keavney B D, Lowe G D, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651–658
   PubMed Web of Science ®Google Scholar
• Branch W, Eller A G. Antiphospholipid syndrome and thrombosis. Clin Obstet Gynecol 2006; 49: 861–874
   PubMed Web of Science ®Google Scholar
• Opatrny L, David M, Kahn S R, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33: 2214–2221
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin M D, Atsumi T, Branch D W, Brey R L, Cervera R, Derksen R H, DE Groot P G, Koike T, Meroni P L, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306
   PubMed Web of Science ®Google Scholar
• Kaul M S, Erkan D, Sammaritano L, Lockshin M D. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007; 66: 927–930
   PubMed Web of Science ®Google Scholar
• Wu S, Stephenson M D. Obstetrical antiphospholipid syndrome. Semin Reprod Med 2006; 24: 40–53
   PubMed Web of Science ®Google Scholar
• Middeldorp S. Thrombophilia and pregnancy complications: cause or association?. J Thromb Haemost 2007; 5(Suppl 1)276–282
   PubMed Web of Science ®Google Scholar
• Coulam C B, Jeyendran R S, Fishel L A, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55: 360–368
   PubMed Web of Science ®Google Scholar
• Krabbendam I, Franx A, Bots M L, Fijnheer R, Bruinse H W. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005; 118: 143–153
   PubMed Web of Science ®Google Scholar
• Robertson L, Wu O, Greer I. Thrombophilia and adverse pregnancy outcome. Curr Opin Obstet Gynecol 2004; 16: 453–458
   PubMed Web of Science ®Google Scholar
• Brenner B. Thrombophilia and adverse pregnancy outcome. Obstet Gynecol Clin North Am 2006; 33: 443–456
   PubMed Web of Science ®Google Scholar
• Stella C L, Sibai B M. Thrombophilia and adverse maternal–perinatal outcome. Clin Obstet Gynecol 2006; 49: 850–860
   PubMed Web of Science ®Google Scholar
• Roque H, Paidas M J, Funai E F, Kuczynski E, Lockwood C J. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 290–295
   PubMed Web of Science ®Google Scholar
• Lissalde-Lavigne G, Cochery-Nouvellon E, Mercier E, Quere I, Dauzat M, Mares P, Gris J C. The association between hereditary thrombophilias and pregnancy loss. Haematologica 2005; 90: 1223–1230
   PubMed Web of Science ®Google Scholar
• Makikallio K, Tekay A, Jouppila P. Yolk sac and umbilicoplacental hemodynamics during early human embryonic development. Ultrasound Obstet Gynecol 1999; 14: 175–179
   PubMed Web of Science ®Google Scholar
• Brenner B. Thrombophilia and pregnancy complications. Pathophysiol Haemost Thromb 2006; 35: 28–35
   PubMedGoogle Scholar
• Brenner B. Thrombophilia and pregnancy loss in first intended pregnancy. J Thromb Haemost 2005; 3: 2176–2177
   PubMed Web of Science ®Google Scholar
• Gris J C, Lissalde-Lavigne G, Quere I, Dauzat M, Mares P. Prophylaxis and treatment of thrombophilia in pregnancy. Curr Opin Hematol 2006; 13: 376–381
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer K A, Donati M B, Gould M, Samama M M, Weitz J I. Parenteral anticoagulants: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 141S–159S
   PubMedGoogle Scholar
• Ibbotson T, Perry C M. Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002; 62: 2283–2314
   PubMed Web of Science ®Google Scholar
• Cheng J W. Fondaparinux: a new antithrombotic agent. Clin Ther 2002; 24: 1757–1769
   PubMed Web of Science ®Google Scholar
• Walenga J M, Jeske W P, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005; 14: 847–858
   PubMed Web of Science ®Google Scholar
• Ng H J, Crowther M A. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006; 43: S77–S83
   Web of Science ®Google Scholar
• Samama M M, Gerotziafas G. New antitoagulants. Ann Pharm Fr 2007; 65: 85–94
   PubMedGoogle Scholar
• Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 160S–198S
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 199S–233S
   PubMedGoogle Scholar
• Holzgreve W, Carey J C, Hall B D. Warfarin-induced fetal abnormalities. Lancet 1976; 2: 914–915
   PubMed Web of Science ®Google Scholar
• Schaefer C, Hannemann D, Meister R, Elefant E, Paulus W, Vial T, Reuvers M, Robert-Gnansia E, Arnon J, De S M, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95: 949–957
   PubMed Web of Science ®Google Scholar
• Raghav S, Reutens D. Neurological sequelae of intrauterine warfarin exposure. J Clin Neurosci 2007; 14: 99–103
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H. Anticoagulation during pregnancy. Semin Thromb Hemost 2003; 29: 633–638
   PubMed Web of Science ®Google Scholar
• Kher A, Bauersachs R, Nielsen J D. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 2007; 97: 505–513
   PubMed Web of Science ®Google Scholar
• Bircher A J, Harr T, Hohenstein L, Tsakiris D A. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006; 61: 1432–1440
   PubMed Web of Science ®Google Scholar
• Eikelboom J W, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006; 96: 547–552
   PubMed Web of Science ®Google Scholar
• Warkentin T E, Greinacher A, Koster A, Lincoff A M. Treatment and prevention of heparin-induced thrombocytopenia: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 340S–380S
   PubMedGoogle Scholar
• Geerts W H, Bergqvist D, Pineo G F, Heit J A, Samama C M, Lassen M R, Colwell C W. Prevention of venous thromboembolism: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 381S–453S
   PubMedGoogle Scholar
• Greer I A, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401–407
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynecologists. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. ed. RCOG Press, London 2007, Guideline No. 28
   Google Scholar
• Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002; 28: 439–446
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Kreutzenbeck H J, Magnani H N. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93: 63–69
   PubMed Web of Science ®Google Scholar
• Bergqvist D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag 2006; 2: 365–370
   PubMedGoogle Scholar
• Nijkeuter M, Huisman M V. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Curr Opin Pulm Med 2004; 10: 338–344
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal M A. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569–1570
   PubMed Web of Science ®Google Scholar
• Dempfle C E. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914–1915
   PubMed Web of Science ®Google Scholar
• CLASP. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br J Obstet Gynaecol 1995; 102: 861–868
   PubMedGoogle Scholar
• CLASP. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) collaborative group. Lancet 1994; 343: 619–629
   PubMed Web of Science ®Google Scholar
• Albers G W, Amarenco P, Easton J D, Sacco R L, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: ACCP Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133: 630S–669S
   PubMedGoogle Scholar
• Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007; 5: 45–55
   PubMedGoogle Scholar
• Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect 2006; 19: 253–259
   PubMedGoogle Scholar
• Galla J M, Lincoff A M. The role of clopidogrel in the management of ischemic heart disease. Curr Opin Cardiol 2007; 22: 273–279
   PubMed Web of Science ®Google Scholar
• Tricoci P, Peterson E D. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. J Interv Cardiol 2006; 19: 449–455
   PubMedGoogle Scholar
• Hague W M, North R A, Gallus A S, Walters B N, Orlikowski C, Burrows R F, Cincotta R B, Dekker G A, Higgins J R, Lowe S A, et al. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001; 175: 258–263
   PubMed Web of Science ®Google Scholar
• Zotz R B, Gerhardt A, Scharf R E. Pregnancy-associated venous thromboembolic disease: prediction, prevention, and therapy. Haemostaseologie 2006; 26: 63–71
   PubMedGoogle Scholar
• Krivak T C, Zorn K K. Venous thromboembolism in obstetrics and gynecology. Obstet Gynecol 2007; 109: 761–777
   PubMed Web of Science ®Google Scholar
• Duhl A J, Paidas M J, Ural S H, Branch W, Casele H, Cox-Gill J, Hamersley S L, Hyers T M, Katz V, Kuhlmann R, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457.e1–21
   Web of Science ®Google Scholar
• ACOG. ACOG Practice Bulletin No. 84: prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol 2007; 110: 429–440
   PubMedGoogle Scholar
• Baglin T P, Keeling D M, Watson H G. Guidelines on oral anticoagulation (warfarin): 3rd ed. – 2005 update. Br J Haematol 2006; 132: 277–285
   PubMed Web of Science ®Google Scholar
• Vandermeulen E. Is anticoagulation and central neural blockade a safe combination. Curr Opin Anaesthesiol 1999; 12: 539–543
   PubMedGoogle Scholar
• Horlocker T T, Wedel D J, Benzon H, Brown D L, Enneking F K, Heit J A, Mulroy M F, Rosenquist R W, Rowlingson J, Tryba M, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28: 172–197
   PubMed Web of Science ®Google Scholar
• Kozek S. Modern anaesthesiological techniques and anticoagulation. Haemostaseologie 2006; 26: S41–S51
   Google Scholar
• Parvizi J, Viscusi E R, Frank H G, Sharkey P F, Hozack W J, Rothman R R. Can epidural anesthesia and warfarin be coadministered. Clin Orthop Relat Res 2006; 456: 133–137
   Google Scholar
• Chan W S, Anand S, Ginsberg J S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191–196
   PubMedGoogle Scholar
• The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761–781
   PubMed Web of Science ®Google Scholar
• Barbour L A, Oja J L, Schultz L K. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024–1029
   PubMed Web of Science ®Google Scholar
• Carp H J. Thrombophilia and recurrent pregnancy loss. Obstet Gynecol Clin North Am 2006; 33: 429–442
   PubMed Web of Science ®Google Scholar
• Coppens M, Folkeringa N, Teune M J, Hamulyak K, van der M J, Prins M H, Buller H R, Middeldorp S. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 2007; 5: 1444–1448
   PubMed Web of Science ®Google Scholar
• Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – Yes. J Thromb Haemost 2003; 1: 2070–2072
   PubMed Web of Science ®Google Scholar
• Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – No. J Thromb Haemost 2003; 1: 2073–2074
   PubMed Web of Science ®Google Scholar
• Walker M C, Ferguson S E, Allen V M. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database Syst Rev 2003, CD003580
   Google Scholar
• Gris J C, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland M L, Dauzat M, Mares P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695–3699
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3: 227–229
   PubMed Web of Science ®Google Scholar
• Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 2004; 103: 4003–4009
   PubMed Web of Science ®Google Scholar
• Askie L M, Duley L, Henderson-Smart D J, Stewart L A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791–1798
   PubMed Web of Science ®Google Scholar
• Lim W, Crowther M A, Eikelboom J W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 1050–1057
   PubMed Web of Science ®Google Scholar
• Petri M, Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2006; 32: 591–607
   PubMed Web of Science ®Google Scholar
• Galli M. Improving management of pregnancy in antiphospholipid antibody-positive women. J Rheumatol 2006; 33: 2108–2109
   PubMed Web of Science ®Google Scholar
• Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005, CD002859
   PubMed Web of Science ®Google Scholar
• Noble L S, Kutteh W H, Lashey N, Franklin R D, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684–690
   PubMed Web of Science ®Google Scholar
• Branch D W, Porter T F, Paidas M J, Belfort M A, Gonik B. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J Allergy Clin Immunol 2001; 108: S133–S138
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Farquharson R G, Christiansen O B, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006; 21: 2216–2222
   PubMed Web of Science ®Google Scholar